Genelux’s (GNLX) Buy Rating Reiterated at HC Wainwright

Genelux (NASDAQ:GNLX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock.

Genelux Stock Down 12.5 %

Shares of Genelux stock traded down $0.49 on Tuesday, reaching $3.41. The company’s stock had a trading volume of 320,841 shares, compared to its average volume of 228,249. The company has a market capitalization of $117.60 million, a price-to-earnings ratio of -3.58 and a beta of -1.41. Genelux has a 52 week low of $1.60 and a 52 week high of $6.50. The firm’s fifty day simple moving average is $4.00 and its two-hundred day simple moving average is $3.09.

Institutional Investors Weigh In On Genelux

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Genelux during the 3rd quarter valued at $59,000. Geode Capital Management LLC lifted its holdings in Genelux by 39.7% in the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after acquiring an additional 89,854 shares during the period. Apollon Wealth Management LLC lifted its stake in shares of Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after purchasing an additional 2,857 shares during the period. D.A. Davidson & CO. purchased a new stake in Genelux during the fourth quarter valued at approximately $51,000. Finally, LifeSteps Financial Inc. raised its position in Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after acquiring an additional 8,715 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.